Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 1147-1158

  Nagaraju, Ganji Purnachandra ^a,b   Long, Tua Elisabeth ^b   Park, Wungki ^b   Landry, Jerome C ^b   Taliaferro Smith, Latonia ^a,b   Farris, Alton B ^b   Diaz, Roberto ^b   El Rayes, Bassel F ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; EMT; Ganetespib; HSP90; Metastasis

Indexed keywords

GANETESPIB; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; UVOMORULIN; VIMENTIN; CADHERIN; COLLAGEN; DRUG COMBINATION; LAMININ; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHEROID CELL; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL MOTION; COLORECTAL TUMOR; DRUG COMBINATION; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG COMBINATIONS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LAMININ; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTEOGLYCANS; SIGNAL TRANSDUCTION; UP-REGULATION; VIMENTIN;

EID: 84941629402     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22185     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
3. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008; 14:818-829.
4. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2012; 62:1315-1326.
5. Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131:830-840.
6. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9:265-273.
7. Gondi CS, Dinh DH, Klopfenstein JD, Gujrati M, Rao JS. MMP-2 downregulation mediates differential regulation of cell death via ErbB-2 in glioma xenografts. Int J Oncol 2009; 35:257-263.
8. Zhou H, Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev™ Eukaryot Gene Expr 2010; 20:1-16.
9. Ting W-C, Chen L-M, Pao J-B, et al. Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci 2013; 10:1022-1027.
10. Babykutty S, PS P, RJ N, et al. Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-κB in colon cancer cells. Mol Carcinog 2012; 51:475-490.
11. Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010; 49:805-811.
12. Khaleghpour K, Li Y, Banville D, Yu Z, Shen S-H. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25:241-248.
13. Jiang J, Tang Y-L, Liang X-H. EMT: A new vision of hypoxia promoting cancer progression. Cancer Biol Ther 2011; 11:714-723.
14. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63:1138-1143.
15. Nagendraprabhu P, Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Investig New Drugs 2011; 29:207-224.
16. Su C-C, Chen G-W, Lin J-G, Wu L-T, Chung J-G. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B/p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006; 26:1281-1288.
17. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009; 6:327-334.
18. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5835.
19. Carrneliet P, Dor Y, Herbert J, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 395:525.
20. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008; 29:2267-2278.
21. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008; 104:733-744.
22. Wu K, Bonavida B. The activated NF-κB-snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev™ Immunol 2009; 29:241-256.
23. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013; 13:152-161.
24. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11:475-484.
25. Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investig New Drugs 2012; 30:2201-2209.
26. Lin T-Y, Bear M, Du Z, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors. Exp Hematol 2008; 36:1266-1277.
27. Nagaraju GP, Park W, Wen J, et al. Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 2013; 16:919.
28. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 1999; 3:15-32.
29. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001; 21:146-170.
30. Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 2011; 26:391-397.
31. Damodharan U, Ganesan R, Radhakrishnan UC. Expression of MMP2 and MMP9 (gelatinases A and B) in human colon cancer cells. Appl Biochem Biotechnol 2011; 165:1245-1252.
32. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer-Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006; 119:1403-1411.
33. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-1128.
34. Sakakibara K, Liu B, Hollenbeck S, Kent KC. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 2005; 288:H2861-H2868.
35. Sarbassov DD, Ali SM, Kim D-H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-1302.
36. Berven LA, Willard FS, Crouch MF. Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296:183-195.
37. Liu L, Chen L, Chung J, Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008; 27:4998-5010.